284 related articles for article (PubMed ID: 36440853)
1. What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
Straub CJ; Rusali LE; Kremiller KM; Riley AP
J Med Chem; 2023 Jan; 66(1):107-121. PubMed ID: 36440853
[TBL] [Abstract][Full Text] [Related]
2. DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ; Witt-Enderby PA; Surratt CK
ACS Chem Neurosci; 2018 Oct; 9(10):2475-2483. PubMed ID: 30216039
[TBL] [Abstract][Full Text] [Related]
3. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.
Maciulaitis R; Kontrimaviciute V; Bressolle FM; Briedis V
Hum Exp Toxicol; 2008 Mar; 27(3):181-94. PubMed ID: 18650249
[TBL] [Abstract][Full Text] [Related]
4. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.
Maisonneuve IM; Glick SD
Pharmacol Biochem Behav; 2003 Jun; 75(3):607-18. PubMed ID: 12895678
[TBL] [Abstract][Full Text] [Related]
5. [Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action].
Kazlauskas S; Kontrimaviciūte V; Sveikata A
Medicina (Kaunas); 2004; 40(3):216-9. PubMed ID: 15064541
[TBL] [Abstract][Full Text] [Related]
6. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration.
Pace CJ; Glick SD; Maisonneuve IM; He LW; Jokiel PA; Kuehne ME; Fleck MW
Eur J Pharmacol; 2004 May; 492(2-3):159-67. PubMed ID: 15178360
[TBL] [Abstract][Full Text] [Related]
7. Development of novel medications for drug addiction. The legacy of an African shrub.
Glick SD; Maisonneuve IM
Ann N Y Acad Sci; 2000; 909():88-103. PubMed ID: 10911925
[TBL] [Abstract][Full Text] [Related]
8. Ibogaine in the treatment of substance dependence.
Brown TK
Curr Drug Abuse Rev; 2013 Mar; 6(1):3-16. PubMed ID: 23627782
[TBL] [Abstract][Full Text] [Related]
9. Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga.
Paškulin R; Jamnik P; Danevčič T; Koželj G; Krašovec R; Krstić-Milošević D; Blagojević D; Strukelj B
J Ethnopharmacol; 2012 Aug; 143(1):319-24. PubMed ID: 22751004
[TBL] [Abstract][Full Text] [Related]
10. [Ibogaine - structure, influence on human body, clinical relevance].
Zdrojewicz Z; Kuszczak B; Olszak N
Pol Merkur Lekarski; 2016 Jul; 41(241):50-55. PubMed ID: 27734823
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.
Kuehne ME; He L; Jokiel PA; Pace CJ; Fleck MW; Maisonneuve IM; Glick SD; Bidlack JM
J Med Chem; 2003 Jun; 46(13):2716-30. PubMed ID: 12801235
[TBL] [Abstract][Full Text] [Related]
12. Facilitation of memory retrieval by the "anti-addictive" alkaloid, ibogaine.
Popik P
Life Sci; 1996; 59(24):PL379-85. PubMed ID: 8950313
[TBL] [Abstract][Full Text] [Related]
13. Coronaridine congeners modulate mitochondrial α3β4* nicotinic acetylcholine receptors with different potency and through distinct intra-mitochondrial pathways.
Arias HR; Lykhmus O; Uspenska K; Skok M
Neurochem Int; 2018 Mar; 114():26-32. PubMed ID: 29277577
[TBL] [Abstract][Full Text] [Related]
14. Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.
Glick SD; Sell EM; Maisonneuve IM
Eur J Pharmacol; 2008 Dec; 599(1-3):91-5. PubMed ID: 18930043
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of α3β4 Nicotinic Acetylcholine Receptor Modulators Derived from Aristoquinoline That Reduce Reinstatement of Cocaine-Seeking Behavior.
Rusali LE; Lopez-Hernandez AM; Kremiller KM; Kulkarni GC; Gour A; Straub CJ; Argade MD; Peters CJ; Sharma A; Toll L; Cippitelli A; Riley AP
J Med Chem; 2024 Jan; 67(1):529-542. PubMed ID: 38151460
[TBL] [Abstract][Full Text] [Related]
16. Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.
Rodríguez-Cano BJ; Kohek M; Ona G; Alcázar-Córcoles MÁ; Dos Santos RG; Hallak JEC; Bouso JC
Drug Alcohol Rev; 2023 Feb; 42(2):401-414. PubMed ID: 36456173
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
Glick SD; Maisonneuve IM; Kitchen BA; Fleck MW
Eur J Pharmacol; 2002 Mar; 438(1-2):99-105. PubMed ID: 11906717
[TBL] [Abstract][Full Text] [Related]
18. Receptor protection studies comparing recombinant and native nicotinic receptors: Evidence for a subpopulation of mecamylamine-sensitive native alpha3beta4* nicotinic receptors.
Free RB; Kaser DJ; Boyd RT; McKay DB
Neurosci Lett; 2006 Jan; 392(1-2):135-9. PubMed ID: 16198480
[TBL] [Abstract][Full Text] [Related]
19. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
Mash DC; Kovera CA; Pablo J; Tyndale RF; Ervin FD; Williams IC; Singleton EG; Mayor M
Ann N Y Acad Sci; 2000 Sep; 914():394-401. PubMed ID: 11085338
[TBL] [Abstract][Full Text] [Related]
20. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.
Toll L; Zaveri NT; Polgar WE; Jiang F; Khroyan TV; Zhou W; Xie XS; Stauber GB; Costello MR; Leslie FM
Neuropsychopharmacology; 2012 May; 37(6):1367-76. PubMed ID: 22278092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
